BWXT Q2 EPS Beats, Guidance Raised Across Board; Medical Unit Sold
BWXT sits 22% above its 52-week low of $143.07.
Summary
BWXT delivered a mixed Q2: revenue of $901.6M slightly missed the $902.63M consensus, but adjusted EPS of $1.07 beat by 3 cents and adjusted EBITDA of $155.5M topped estimates by $5M. The company also announced the sale of its medical business and closed the Precision Components Group acquisition. Full-year guidance was raised across all metrics—revenue to ~$3.8B, adjusted EBITDA to $662M-$672M, non-GAAP EPS to $4.70-$4.80, and free cash flow to $345M-$360M—all above prior ranges. This follows the earlier headline on raised revenue guidance, but adds the Q2 results and the full scope of the guidance increase. The guidance raise and EPS beat signal strong operational momentum, though the slight revenue miss may temper enthusiasm.
At the time of this announcement, BWXT was trading at $174.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $143.07 to $241.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.